Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective
Clin Pharmacol Ther
.
2024 Mar 27.
doi: 10.1002/cpt.3242.
Online ahead of print.
Authors
Mohamed-Eslam F Mohamed
1
,
Sandhya Girish
2
,
Rita Humeniuk
2
,
Silpa Nuthalapati
1
,
Amit Desai
3
,
Amita Datta-Mannan
4
,
Ferdous Gheyas
5
,
Jitendra Kanodia
6
,
Sravanthi Cheeti
7
,
Tong Zhu
3
Affiliations
1
Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
2
Clinical Pharmacology, Gilead Sciences, Inc., Foster City, California, USA.
3
Astellas Pharma Global Development, Northbrook, Illinois, USA.
4
Exploratory Medicine and Pharmacology, Eli Lilly & Co., Indianapolis, Indiana, USA.
5
Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey, USA.
6
Translational Biology, Xencor Inc., Pasadena, California, USA.
7
Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
PMID:
38536001
DOI:
10.1002/cpt.3242
No abstract available